Literature DB >> 2917194

Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model.

A Gruber1, J H Griffin, L A Harker, S R Hanson.   

Abstract

The in vivo antithrombotic properties of human plasma activated protein C (APC), a natural anticoagulant enzyme, were investigated in a baboon model of thrombus formation on prosthetic vascular grafts. Infusion of 0.25 to 1.1 mg/kg/h purified, human, APC inhibited blood clotting, as measured by the activated partial thromboplastin time (APTT), and reduced vascular graft platelet deposition by 40% to 70%, as determined by the real-time scintillation camera imaging of 111In-labeled platelet deposition. APC infusion also preserved graft patency. Hemostatic plug formation remained normal, as measured by the template bleeding times. These results suggest that APC administration may produce immediate antithrombotic effects under arterial flow conditions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917194

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

2.  Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.

Authors:  András Gruber; Ulla M Marzec; Leslie Bush; Enrico Di Cera; José A Fernández; Michelle A Berny; Erik I Tucker; Owen J T McCarty; John H Griffin; Stephen R Hanson
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

Review 3.  Activated protein C: biased for translation.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

4.  Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis.

Authors:  Erik I Tucker; Norah G Verbout; Philberta Y Leung; Sawan Hurst; Owen J T McCarty; David Gailani; András Gruber
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

5.  Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model.

Authors:  M J Heeb; U Marzec; A Gruber; S R Hanson
Journal:  Thromb Haemost       Date:  2012-02-28       Impact factor: 5.249

6.  Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice.

Authors:  Toshiaki Shirai; Alexey S Revenko; Justin Tibbitts; Anh T P Ngo; Annachiara Mitrugno; Laura D Healy; Jennifer Johnson; Erik I Tucker; Monica T Hinds; Lisa M Coussens; Owen J T McCarty; Brett P Monia; András Gruber
Journal:  Blood Adv       Date:  2019-10-22

7.  Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin.

Authors:  W A Dittman; T Kumada; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

8.  Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.

Authors:  S R Hanson; J H Griffin; L A Harker; A B Kelly; C T Esmon; A Gruber
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Transgenic mice expressing recombinant human protein C exhibit defects in lactation and impaired mammary gland development.

Authors:  Carol A Palmer; Henryk Lubon; James L McManaman
Journal:  Transgenic Res       Date:  2003-06       Impact factor: 2.788

10.  Thrombomodulin improves early outcomes after intraportal islet transplantation.

Authors:  W Cui; J T Wilson; J Wen; J Angsana; Z Qu; C A Haller; E L Chaikof
Journal:  Am J Transplant       Date:  2009-05-20       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.